WO2022090801 - PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
National phase entry:
Publication Number
WO/2022/090801
Publication Date
05.05.2022
International Application No.
PCT/IB2021/000745
International Filing Date
26.10.2021
Title **
[English]
PVRL2 AND/OR PVRIG AS BIOMARKERS FOR TREATMENT
[French]
PVRL2 ET/OU PVRIG EN TANT QUE BIOMARQUEURS DE TRAITEMENT
Applicants **
COMPUGEN LTD.
Inventors
FRENKEL, Masha
OPHIR, Eran
KLIGER, Yossef
WEYL, Emmanuel
COJOCARU, Gad, S.
KFIR, Tal, Fridman
NOVIK, Amit
SABATH, Niv
ALTEBER, Zoya
Priority Data
63/257,026
18.10.2021
US
63/105,782
26.10.2020
US
63/213,629
22.06.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 10901 | |
| EPO | Filing, Examination, Granting | 219567 | |
| Japan | Filing, Examination, Granting | 5306 | |
| South Korea | Filing, Examination, Granting | 12864 | |
| USA | Filing, Examination, Granting | 52090 |
Total:
300,728
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention provides biomarkers for use in determining populations for treatment with anti-PVRIG antibodies and such biomarkers include, for example PVRIG and/or PVRL2 expression.[French]
La présente invention concerne des biomarqueurs destinés à être utilisés dans la détermination de populations pour un traitement avec des anticorps anti-PVRIG et ces biomarqueurs comprenant, par exemple, l'expression de PVRIG et/ou PVRL2.